PRESS RELEASE: CMC Contrast granted Orphan Drug Designation by the FDA for its liver specific MRI contrast media CMC-001

Lund, Sweden, 27 November, 2013 – CMC Contrast AB, a privately owned drug development company that is developing a targeted contrast agent for Magnetic Resonance Imaging (MRI), announced today that Orphan Drug Designation has been granted by the US Food and Drug Administration (FDA) for its liver specific contrast agent CMC-001. The Orphan Drug Designation…

Read More